Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 97
- Registration Number
- NCT03397394
- Locations
- 🇺🇸
University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Northwestern University, Chicago, Chicago, Illinois, United States
🇺🇸Miami Cancer Institute, Baptist Health South Florida, Miami, Florida, United States
Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT02986100
- Locations
- ðŸ‡ðŸ‡º
PRA Magyarország Kft., Budapest, Rottenbiller Utca 13, Hungary
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 405
- Registration Number
- NCT02975934
- Locations
- 🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸Texas Oncology Cancer Center-Round Rock, Round Rock, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 277
- Registration Number
- NCT02952534
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Atlanta Urological Group, Atlanta, Georgia, United States
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 349
- Registration Number
- NCT02855944
- Locations
- 🇵🇱
Bialostockie Centrum Onkologii im. Marii Sklodowskiej-Curie, Bialystok, Poland
🇺🇦Volyn Regional Oncology Dispensary, Lutsk, Ukraine
🇺🇦Sumy Regional Oncology Center, Sumy, Ukraine
Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 17
- Registration Number
- NCT02740712
- Locations
- 🇵🇱
BioVirtus Research Site, Kajetany, Mokra 7, Poland
🇵🇱Zachodniopomorskie Centrum Onkologii Centrum Innowacji, Szczecin, Poland
🇵🇱Med Polonia, Poznan, Poland
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 248
- Registration Number
- NCT02654990
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇳🇱VUmc, Hematology, PK2 BR012, Amsterdam, Netherlands
🇳🇱Albert Schweitzer ziekenhuis, Hematology, Dordrecht, Netherlands
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 19
- Registration Number
- NCT02042378
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸New York University, New York, New York, United States
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
- Conditions
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 564
- Registration Number
- NCT01968213
- Locations
- 🇺🇸
Saint Jude Heritage Medical Center, Fullerton, California, United States
🇺🇸University of California Los Angeles (UCLA), Santa Monica, California, United States
🇺🇸Johns Hopkins Universty, Baltimore, Maryland, United States
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
- Conditions
- Interventions
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 491
- Registration Number
- NCT01891344
- Locations
- 🇺🇸
Saint Jude Heritage Medical Center, Fullerton, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇦🇺Prince of Wales Hospital, Sydney, New South Wales, Australia